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In general, topical ophthalmic drug products, especially those used for treating infections, present 
low effectiveness because of various reasons, from unfavorable drug physicochemical properties to 
physiological protective mechanisms of the eye. The fact is such group of products holds room for 
improvement, which could mean the development of better drugs or dosage forms. To achieve this, the 
knowledge of market composition is essential. The present work studied and compared the antimicrobial 
ophthalmic markets of Brazil and of the United States (US). Official databank of Brazilian Health 
Regulatory Agency and of US Food and Drug Administration were assessed for registered antimicrobial 
topical ophthalmic drug products. Brazilian market has registered greater number of drug products (119) 
than the US (94), but the latter involves more variety of substances and dosage forms. In both countries, 
non-innovative products registered as solutions of antibacterials, especially fluoroquinolones and 
aminoglycosides lead the market. Despite the clinical demand, the US has only one group of antimycotics 
(polyenes) registered, while in Brazil, there is not any ophthalmic antimycotic product marketed. This 
study evidences there is not only space for development of newer drugs and formulations but also a 
demand for already existing technologies and products in both countries.
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INTRODUCTION
Ophthalmic infections (i.e., orbital cellulitis, 
endophthalmitis, blepharitis, conjunctivitis and keratitis) 
can affect many ocular anatomical structures and are 
caused by different etiological agents (virus, bacteria, 
fungi and parasites). These infections are a common 
cause of morbidity around the world. An epidemiological 
study of primary ophthalmic inpatient admissions in the 
United States (US) from 2001 to 2014 showed the majority 
of the diagnoses was infectious (Iftikhar et al., 2017). 
Accordingly, infections were the second most prevalent 
cause of eye diseases in Brazilian emergencies centers, 
affecting mainly the economically active population 
(Vicente et al., 2016). According to the World Health 
Organization, corneal opacities, mostly triggered by 
infectious diseases, are the 4th cause of blindness and 
visual impairment globally (WHO, 2002a; WHO, 2002b). 
Still, effective topical ophthalmic drug products are 
difficult to be developed because of unfavorable drug 
physicochemical properties of commonly used drugs, but 
mainly because of the particularities of the eye anatomy 
and physiology.
Eyes have constant lachrymal secretion and rapid 
nasolachrymal drainage, which added to the eyelid 
movements can wash out administrated medicines within 
4 to 23 minutes. Furthermore, the maximum volume the 
open eye can accommodate is limited between 20 and 
30 µL. Ophthalmic bioavailability is usually low due to 
natural anatomical barriers and short residence time of 
ophthalmic solutions (Gratieri et al., 2010a; Gratieri et al., 
2011). As a result, to achieve therapeutic results, frequent 
administration of concentrated formulations is needed 
(Labcharoenwongs et al., 2012). Moreover, ophthalmic 
products must be sterile and non-irritating (Mandal et al., 
2012). As conservatives can be toxic to ocular surface 
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(Liang et al., 2011), stability is also an issue. In vitro 
experiments may also be problematic, as viable tissue 
properties must be maintained (Gratieri et al., 2010b). 
Growing resistance of ocular infections, especially against 
antibacterial drugs (Miller et al., 2017), is another factor 
demanding investments and research.
Despite the pharmaceutical technology field 
improvements in the last years, there is still a long way 
to reach the optimum treatment of infectious ophthalmic 
diseases (Coates, Hall, Hu, 2011). The knowledge of 
pharmaceutical market composition regarding topical 
ophthalmic drug products in different countries can be 
useful in designing development strategies and focusing 
investments. Such information is spread and often 
difficult to be obtained. To our knowledge, this is the first 
detailed analysis of current available products in Brazil. 
A comparison was performed with the US market through 
quantitative and qualitative analyzes of registered products 
aiming to determine gaps with potential for investment and 
pharmaceutical development.
MATERIAL AND METHODS
Drug products registered by the Brazilian Health 
Regulatory Agency (ANVISA)
All products registered until May 31, 2016 in 
Brazil for commercialization under the ophthalmic, 
ophthalmologic and ocular routes of administration were 
listed using the official ANVISA databank (DATAVISA) 
according to ANVISA authorizations for academic 
research No. 604279/17-1, 604286/17-4 and 604274/17-1 
– process No. 25351.200950/2017-94, respecting 
confidential data of legal entities. DATAVISA is an 
internal software in which there is administrative and 
technical information about the medicines under ANVISA 
regulation, including due date of the registry, company 
responsible for the registered product (applicant holder), 
marketed and therapeutic category, formulation, dosage 
forms and routes of administration of the products. From 
a preliminary data set, products with the archive wrong 
filled, invalid or expired due date for registry renewal were 
excluded. After data review, only valid products classified 
as “antimicrobials” were analyzed according to regulatory 
characteristics, drug substance, dosage form and applicant 
holder. The results were analyzed in units of registered 
drug products, in which drug products from the same 
applicant holder containing the same drug and the same 
dosage form, but different strengths, volumes, weights 
and/or pharmaceutical units, were counted individually/
separately.
Drug products registered by the US Food and 
Drug Administration (FDA)
Similarly, products registered until May 31, 2016 
in the US under ophthalmic route of administration were 
listed using the official databank of FDA for Approved 
Drugs Products with Therapeutic Equivalence Evaluations 
(Orange Book). The Orange Book is available as an open 
access website (https://www.accessdata.fda.gov/scripts/
cder/ob/) and contains information as the applicant holder, 
marketed status, active ingredient, dosage form, route of 
administration and application number of the products. 
From this preliminary data set, products discontinued 
from marketing were excluded. Only products classified as 
“antimicrobials” were categorized according to regulatory 
characteristics, drug substance, dosage form and applicant 
holder. The results were analyzed in units of registered drug 
products, in which drug products from the same applicant 
holder containing the same drug and the same dosage 
form, but different strengths, volumes, weights and/or 
pharmaceutical units, were counted individually/separately.
RESULTS
The survey showed there were 711 commercialized 
topical ophthalmic drug products in Brazil and 316 in 
the US. From these, 119 corresponded to antimicrobial 
drugs in Brazil and 94 in the US. In this paper, they were 
classified in accordance to pharmacological groups, 
including antiseptics, antibacterials, antimycotics and 
antivirals, combined or not to corticosteroids as anti-
inflammatories (Figure 1). The major group was composed 
of antibacterials, followed by antivirals and antimycotics.
FIGURE 1 - Pharmacological groups registered for ophthalmic 
products in Brazil and in the United States.
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Considering products with only one drug substance, 
fluoroquinolones represented the main group in both 
countries, followed by aminoglycosides. Groups of 
amphenicols, rifamycins and tetracyclines had little 
representativeness in Brazil and were not available in the 
US. The group of “others” included antiseptics that did 
not have a clear classification (Table I).
In the category of products with two or more 
drug substances, the main combination registered 
in Brazil was fluoroquinolones with corticosteroids. 
In the US, aminoglycosides with corticosteroids, 
aminoglycosides with polymixins and corticosteroids, and 
aminoglycosides with polymixins and peptides comprised 
usual combinations (Table II).
Solution was the most relevant dosage form of 
antimicrobial topical ophthalmic drug products in both 
countries, followed by ointment and suspension. The dosage 
form gel has only been registered in the US (Figure 2).
The survey also revealed the Brazilian market is 
constituted mostly by generic and similar drug products 
TABLE I - Comparison of drug substances groups registered as simple ophthalmic products in Brazil and in the United States
Drug groups Drug names
Registered drug products (units)
Brazil United States
Generic Similar  New product Total ANDA
a NDAa Total
5-substituted 
2’-deoxyuridine 
analogues
trifluridine 1 1 2
Acyclic guanosine 
analogues
acyclovir 2 2 4
ganciclovir 1 1
Aminoglycosides
gentamicin sulfate 2 2 8 8
tobramycin 4 14 18 4 2 6
Amphenicols
chloramphenicol 1 1
chloramphenicol 
palmitate 1 1
Fluoroquinolones
besifloxacin 
hydrochloride 1 1
ciprofloxacin 
hydrochloride 8 6 14 6 2 8
gatifloxacin 4 4 2 2 4
levofloxacin 3 3
moxifloxacin 
hydrochloride 3 2 5
ofloxacin 22 2 24 7 1 8
Macrolides
azithromycin 1 1
erythromycin 3 3
Peptides bacitracin 1 1
Polyenes natamycin 1 1
Rifamycins rifamycin SV sodium 1 1
Sulphonamides sulfacetamide sodium 5 5
Tetracyclines tetracycline chloridrate 1 1
Othersb
povidone-iodine 1 1
silver vitellinate 1 1
aAbbreviated New Drug Application (ANDA); New Drug Application (NDA); b The category of “Others” included antiseptics 
that did not have a clear classification. 
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TABLE II - Comparison of drug substances groups registered as combined ophthalmic products in Brazil and in the United States
Drug groups Drug names
Registered drug products (units)
Brazil United States
Generic Similar  New product Total ANDA
a NDAa Total
Aminoglycosides + 
Corticosteroids
gentamicin sulfate + 
prednisolone acetate 2 2
neomycin sulfate + 
dexamethasone sodium 
phosphate
1 1
neomycin sulfate + 
fluorometholone
1 1
tobramycin + 
dexamethasone 1 1 1 3 4
tobramycin + loteprednol 
etabonate 3 3 1 1
Aminoglycosides + 
Polymyxins
neomycin sulfate + 
polymyxin B sulfate 1 1
Aminoglycosides 
+ Polymyxins + 
Corticosteroids
neomycin sulfate + 
polymyxin B sulfate + 
dexamethasone
4 2 6
neomycin sulfate + 
polymyxin B sulfate + 
hydrocortisone
1 1
neomycin sulfate + 
polymyxin B sulfate + 
prednisolone acetate
2 2
Aminoglycosides + 
Polymyxins + Peptides 
neomycin sulfate + 
polymyxin B sulfate + 
bacitracin zinc
3 1 4
neomycin sulfate + 
polymyxin B sulfate + 
gramicidin
3 3
Aminoglycosides + 
Polymyxins + Peptides 
+ Corticosteroids
neomycin sulfate + 
polymyxin B sulfate 
+ bacitracin zinc + 
hydrocortisone
2 2
neomycin sulfate + 
polymyxin B sulfate + 
bacitracin + hydrocortisone 
acetate
1 1
Fluoroquinolones + 
Corticosteroids 
ciprofloxacin hydrochloride 
+ dexamethasone 11 20 31
gatifloxacin + prednisolone 
acetate 2 2
moxifloxacin hydrochloride 
+ dexamethasone sodium 
phosphate
1 1
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Drug groups Drug names
Registered drug products (units)
Brazil United States
Generic Similar  New product Total ANDA
a NDAa Total
Folate antagonists + 
Polymyxins 
trimethoprim sulfate + 
polymyxin B sulfate 3 1 4
Peptides + Polymycins bacitracin zinc + polymyxin B sulfate 3 3
Sulphonamides + 
Corticosteroids 
sulfacetamide sodium + 
prednisolone acetate 1 1 2
sulfacetamide sodium 
+ prednisolone sodium 
phosphate
2 2
Tetracyclines + 
Polymycins
oxytetracycline 
hydrochloride + polymyxin 
B sulfate
5 5 1 1
aAbbreviated New Drug Application (ANDA); New Drug Application (NDA).
FIGURE 2 - Dosage forms registered for ophthalmic products 
in Brazil and in the United States.
TABLE II - Comparison of drug substances groups registered as combined ophthalmic products in Brazil and in the United States 
(cont.)
(80.7%). This scenario is similar to the US, in which 
there were more Abbreviated New Drug Application 
(ANDA) (72.3%) than New Drug Application (NDA) 
(27.7%). Even though Brazilian industries are the main 
applicant holders in the Brazilian market (72.3%), they 
only commercialize similar and generic products, while 
multinational industries have similar, generic and new 
products registered (Figure 3).
DISCUSSION
ANVISA has registered a greater number of 
topical antimicrobial ophthalmic drug products than the 
FDA; however, in the US, more variety of products was 
encountered. While in the US there were 30 simple and 
combined drug substances divided into 17 groups, in 
Brazil there were 21 substances divided into 12 groups.
Combined ophthalmic products containing 
corticosteroids and antimicrobials were relevant in the 
markets analyzed, reaching 35.3% in Brazil and 22.3% 
in the US. The American Academy of Ophthalmology, 
at the Cornea/external disease summary benchmarks for 
Preferred Practice Pattern® Guidelines, highlights a series 
of precautions in the use of corticosteroids as adjuvant 
therapy for ocular infections. In general, corticosteroids, 
if indicated, should be prescribed at the lowest frequency 
and potency available. Long-term corticosteroid therapy 
should be avoided or reduced and, in some cases, 
even eliminated before the use of antimicrobials. Re-
evaluations of the patient should be conducted closely to 
monitor adverse effects, such as corneal melting, cataract 
formation and increased intraocular pressure (American 
Academy of Ophthalmology, 2016), especially with the 
use of dexamethasone (Sheppard, Comstock, Cavet, 
2016). Nevertheless, many of combined products have 
a corticosteroid in the formulation, probably pursuing a 
better patient compliance on a simpler and more economic 
therapeutic scheme.
Interestingly, the biggest combined group in Brazil, 
fluoroquinolones with corticosteroids, did not have a 
single drug product registered in the US. Indeed, when 
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fluoroquinolones are combined with corticosteroids, the 
maximum recommended treatment period is shorted in 
comparison to fluoroquinolones alone, possibly because 
of adverse effects risks of long-term corticosteroid therapy. 
Another drawback of corticosteroid combinations is the 
limited possibilities of the antibacterial treatments. E.g., 
simple product containing ciprofloxacin hydrochloride 
is indicated for the treatment of infections caused by 
Pseudomonas aeruginosa, but the combined product with 
corticosteroid does not have this indication, according 
to product labels. Considering that P. aeruginosa is an 
important etiological agent of ocular infections in the US, 
combined products are not useful in the clinical practice. 
Moreover, the US has a history of microbial resistance 
against fluroquinolones (Asbell et al., 2015) greater than 
the resistance observed in Brazil (Vola et al., 2013), which 
may demand longer treatment periods. Therefore, clinical 
practice in the US has detached the use of fluoroquinolones 
from corticosteroids, explaining the registered products 
pattern. The large presence of fluoroquinolones combined 
with corticosteroids in Brazil may result from differences 
in the profile of microbial resistance and/or the possibility 
of saving in marketing a more complete product by the 
value of the simple antimicrobial product (CMED, 2017).
One of the most serious aspects raised from this 
survey is the high amount of drugs absent from the 
Brazilian market, e.g. 5-substituted 2’-deoxyuridine 
analogues, macrolides, peptides, polyenes, sulphonamides 
and folate antagonists, either in simple or combined forms 
despite the demand. Moreover, Brazil had fewer options of 
newer quinolones generations when compared to the US. 
While Brazil has registered ciprofloxacin hydrochloride 
and ofloxacin (second generation quinolones), gatifloxacin 
and moxifloxacin (fourth generation quinolones), the US 
has registered all previous and also levofloxacin (third 
generation quinolone) and besifloxacin hydrochloride 
(fourth generation quinolone).
In the US, the Gram-positive Staphylococcus 
aureus is the most common bacteria affecting the eye 
globe, mainly the conjunctiva. Still, the Gram-negative 
Pseudomonas aeruginosa has been reported as the 
mainly causative agent for keratitis (Gratieri et al., 
2010b). In Brazil, microbial keratitis is predominantly 
related to Gram-positive bacteria, in special coagulase-
negative Staphylococcus (Yu, Höfling-Lima, Furtado, 
2016), e.g Staphylococcus epidermidis (Ibrahim et al., 
2011), or Staphylococcus aureus (Uesugui et al., 
2002). In conjunctivitis, other important agents include 
Haemophilus spp. (Silva et al., 2012), besides the 
mentioned Staphylococcus aureus (Uesugui et al., 2002). 
Even with some differences in etiological agents in both 
countries, bacteria were relevant infective organisms, both 
Gram-negative and Gram-positive. Hence, the clinical 
routine demands wide spectrum antibacterial drugs. To 
manage bacterial keratitis, Preferred Practice Pattern® 
Guidelines published by the American Academy of 
Ophthalmology recommends the use of fluoroquinolones 
for the majority of antibiotic therapy against Gram-
negative and Gram-positive organisms and even when 
no organism is identified or multiple types of organisms 
are associated to the condition (American Academy of 
Ophthalmology, 2016).
The first marketed quinolone compound was 
the nalidixic acid, being norfloxacin, a 6-fluorinated 
substance, the first fluoroquinolone more similar to 
the modern ones (Appelbaum, Hunter, 2000). Initially, 
quinolones were mostly active against Gram-negative 
bacteria, but evolution of fluoroquinolones molecules and 
newer generations broadened the spectrum of action of 
these substances making them also potent against Gram-
FIGURE 3 - Composition of Brazilian market for ophthalmic products.
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positive bacteria (Blondeau et al., 2000). Staphylococcus 
spp have been related to all kinds of ocular infections 
worldwide with recognized cases of antibiotics resistance. 
Such resistant strains exhibited susceptibility rates above 
80% for fourth-generation fluoroquinolones (Vola et al., 
2013).
Aminoglycosides were the second major group 
registered as simple products in both countries. This group 
presents a similar activity spectrum to quinolones since 
it is mostly effective against Gram-negative bacteria, 
especially P. aeruginosa (Kirst, Marinelli, 2014), but 
it has a lower efficacy against Gram-positive strains 
(Vola et al., 2013). In the US, with the high prevalence 
of P. aeruginosa at keratitis infections, it was compatible 
that there were more products containing aminoglycosides 
(simple and combined) than in Brazil. Aminoglycosides, 
such as tobramycin or gentamicin, are recommended to 
treat bacterial keratitis when no organism is identified or 
multiple types of organisms are associated to the condition 
(American Academy of Ophthalmology, 2016). In this 
way, they are a good option at the empirical treatment, 
according to the American Academy of Ophthalmology.
Although the good efficacy of these antibacterial 
groups, some strains are also developing resistance to 
fluroquinolones (Jhanji et al., 2007), then there is still a 
need to develop new drug substances (Aggen et al., 2010).
Antiviral groups 5-substituted 2’-deoxyuridine 
analogues and acyclic guanosine analogues had few 
representatives registered in both countries: in Brazil, only 
four drug products of acyclovir ointment were available; 
in the US, one drug product of ganciclovir gel and two 
drug products of trifluridine solution were available. All 
these medicines are indicated for topical treatment of 
keratitis caused by herpes simplex virus, according to their 
labels. Ganciclovir gel has also presented good clinical 
efficacy against cytomegalovirus corneal endotheliitis 
(Koizumi et al., 2016). However, viral conjunctivitis and 
keratoconjunctivitis are mostly caused by adenoviruses 
(62% to 80.3%) having the herpes simplex virus low 
prevalence (2.3% to 4.8%). Indeed, adenoviruses seem 
to be more common than bacterial as etiological agent in 
keratoconjunctivitis overall. Thus, antiviral ophthalmic 
market may appear non-correlated to the clinical profile. 
This situation is not exclusive to markets from Brazil 
and the US, since the academic effort has also been 
prioritizing the development of treatments for herpes 
virus infections (Skevaki et al., 2011). Nonetheless, the 
morbidity of these diseases may be considered. Adenoviral 
conjunctivitis is a self-limited disease that can be cured 
in three weeks, while ocular herpes simplex can cause 
blindness (Liesegang et al., 1989) and has recurrence 
and a chronicity tendency (Tran et al., 2016). This could 
explain the pharmaceutical industry focus on more severe 
infections caused by herpes simplex virus. Beyond that, 
viral infection diagnosis, both laboratorial and clinical, 
are complicated, leading to various misdiagnosis as 
bacterial conjunctivitis (Sharma, 2012). In fact, in many 
cases, there is indeed a secondary bacterial infection to 
adenoviral eye infections. Generally antibacterial drugs 
are presumptively prescribed or topical corticosteroids 
used for symptomatic relief (American Academy of 
Ophthalmology, 2016; Skevaki et al., 2010). Anyhow, the 
drugs to treat adenoviral ocular infections can be a health 
need unfulfilled by the industries.
Fungal keratitis is far less common than bacterial 
keratitis, but represents one of the ocular infections 
with poorer prognosis. Since 2006 an alteration at 
etiological agents has been noted: initially caused by 
yeasts, filamentary fungi have become more common 
(Ong et al., 2016). In the US, among the non-bacterial 
isolates, the recovery of molds is the most common, 
above the yeasts (Miller, 2017), e.g. Curvularia spp 33. 
In general, the most common filamentous species are 
Fusarium and Aspergillus, while the most common yeast 
at ocular infections is Candida spp (Thomas, Kaliamurthy, 
2013). In Brazil, Fusarium spp is the major etiological 
agent (Ibrahim et al., 2011; Ibrahim et al., 2009), in 
special the specie Fusarium solani (Yu, Höfling-Lima, 
Furtado, 2016). The recommended treatment for keratitis 
depends on the disease extent, but for superficial lesions 
the topical treatment includes topical azoles, amphotericin 
B, natamycin and caspofungin (amphotericin B or 
fluconazole are especially recommended against yeast, 
while topical natamycin is recommended against hyphae) 
(Thomas, Kaliamurthy, 2013). However, only one 
ophthalmic suspension of natamycin is registered in the 
US by the FDA. There is no antifungal ophthalmic drug 
product registered in the Brazilian market in the period 
analyzed, despite the health demand.
According to Brazilian epidemiological data 
collected in reference centers in the state of São Paulo 
between the years of 2000 and 2004, 66 cases of fungal 
keratitis were confirmed by microbiological analysis. 
Among the treatments performed, evisceration was 
implemented in 15.2%, conjunctival flap was conducted 
in 10.6% and therapeutic penetrating keratoplasty was 
conducted in 39.4% of the patients. Even after treatment, 
57.7% of the patients who passed through therapeutic 
penetrating keratoplasty presented recurrence of fungal 
keratitis or underwent further surgeries, including 
evisceration. These data confirm the high morbidity of 
this disease, which is an important cause of visual loss 
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related to the cornea. Low availability of antifungal agents 
is one of the pointed causes to this overwhelming scenario 
(Ibrahim et al., 2009).
Regarding the dosage form, the majority of 
ophthalmic drug products registered as solutions are 
compatible to the characteristics of the ophthalmic route. 
Solutions usually are presented as a simple formulation 
that is easy to produce and sterilize, besides has a good 
patient acceptance, causing less discomfort to the patient 
than the semisolid dosage forms (Gratieri et al., 2011). 
However, solutions are easily drained out, while semisolid 
dosage forms can provide longer permanence in situ, 
extending drug release (Labcharoenwongs et al., 2012). 
Another advantage of ointments is the administration of 
lipophilic substances (Hazarika, Singh, 2015). The gel 
dosage form was only registered in the US, being the most 
recent ophthalmologic antiviral medicine registered by the 
FDA. Gel is one of the evolutions related to ophthalmic 
formulations because it can incorporate hydrophilic 
compounds, just as solutions, but presents an extended 
release in comparison to eye drops (Ranch et al., 2017). 
At the same time, being more appealing and comfort to 
the patients than the ointments. Nevertheless, there is 
still a need for improvement in terms of bioavailability 
and controlled or sustained drug action. To achieve these 
goals, research has been conducted on in situ gelling 
solutions (Gratieri et al., 2011; Gratieri et al., 2010a), 
nanostructured lipid carriers (Andrade et al., 2016) or 
liposomes for ophthalmic delivery (de Sá et al., 2015). 
Despite the several papers found in the literature that prove 
the superiority of innovative formulations, the present 
survey reveals none of these efforts have been translated 
to the market.
Three categories or application types compose the 
Brazilian market of synthetic drugs: new, similar and 
generic products. The last two are registered as copies 
from the innovator product and, to be approved by 
ANVISA, they must follow specific rules established by 
sanitary legislation. In the US, the equivalent applications 
are denominated Abbreviated Drug Application (ANDA) 
and New Drug Application (NDA). Even with these 
differences, the majority of the medications were copies 
from the innovators in both countries. In comparison to 
the US, Brazil presented a lower rate of new products 
registered. Considering only the Brazilian market, 
Brazilian industries held most of the applications overall, 
but only referred to similar and generic products. All the 
innovator products applications were held by multinational 
industries. In Brazil, new drugs presented the highest 
revenue amongst all the medicine categories, even with a 
lower commercialized quantity than generic and similar 
drugs (ANVISA, 2016). The high added value to new 
products provide an excellent incentive to Brazilian 
industries grow interest in their development.
CONCLUSIONS
Brazilian market has registered greater number 
of drug products (119) than the US (94), but the latter 
involves more variety of substances and dosage forms. 
Simple ophthalmic products were more common than 
combined ones, reaching 59.7% in Brazil and 61.7% 
in the US. The high amount of antibacterial, chiefly 
fluoroquinolones and aminoglycosides, registered as 
topic ophthalmic drug products were compatible with 
the clinical aspects and recommendations in Brazil and 
in the US. Meanwhile, there is need, space and financial 
incentive to develop new antimicrobial drugs and more 
effective ophthalmic formulations, especially to fungal 
and adenoviral ocular infections.
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